Sutro Biopharma, Inc. (STRO)
US — Healthcare Sector
Automate Your Wheel Strategy on STRO
With Tiblio's Option Bot, you can configure your own wheel strategy including STRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STRO
- Rev/Share 0.7994
- Book/Share -0.3106
- PB -2.5559
- Debt/Equity -0.829
- CurrentRatio 2.1602
- ROIC -1.2889
- MktCap 67045459.0
- FreeCF/Share -2.3886
- PFCF -0.3377
- PE -0.269
- Debt/Assets 0.0666
- DivYield 0
- ROE -3.4759
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | STRO | Piper Sandler | Neutral | Overweight | -- | $2 | June 16, 2025 |
| Downgrade | STRO | H.C. Wainwright | Buy | Neutral | -- | -- | March 17, 2025 |
| Downgrade | STRO | BofA Securities | Buy | Underperform | $11 | $1 | March 14, 2025 |
| Downgrade | STRO | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | March 14, 2025 |
| Downgrade | STRO | Wedbush | Outperform | Neutral | $8 | $2 | March 14, 2025 |
News
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
STRO
Published: March 14, 2025 by: Benzinga
Sentiment: Negative
Published: March 14, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Read More
About Sutro Biopharma, Inc. (STRO)
- IPO Date 2018-09-27
- Website https://www.sutrobio.com
- Industry Biotechnology
- CEO Ms. Jane Chung R.Ph.
- Employees 269
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.